Nanovaccines: An effective therapeutic approach for cancer therapy

Gurunathan, Sangiliyandi; Thangaraj, Pratheep; Wang, Lin; Cao, Qilong; Kim, Jin-Hoi

doi:10.1016/j.biopha.2023.115992

Cited by 13 publications

(2 citation statements)

References 323 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanovaccine (majorly based on nanoparticle modification for cellular transport) is more stable, biocompatible, and less toxic. 5,6 Immune response developmentary antigen protein-loaded particles are developed Treg (regulatory T-cells) cells mediated immune response. 7 Nanomedicine becomes a promising solution for breast cancer.…”

Section: Commentarymentioning

confidence: 99%

Nanomedicine: a frontier of the breast cancer treatment

Sonar,

Nyahatkar,

Kalele

et al. 2024

Clinical and Translational Dis

View full text Add to dashboard Cite

Section: Commentarymentioning

confidence: 99%

Nanomedicine: a frontier of the breast cancer treatment

Sonar,

Nyahatkar,

Kalele

et al. 2024

Clinical and Translational Dis

View full text Add to dashboard Cite

“…Cancer nanovaccines have been reviewed from several points of view recently, emphasizing types of nanovaccines and carriers, ideal immune responses, factors determining their efficiency, appropriate antigens and many other important characteristics [202,211,212]. In this review, we presented and discussed main trends regarding cationic nanovaccines and their potential against infectious diseases and cancer.…”

Section: Cationic Nanostructures In Vaccine Design Against Cancermentioning

confidence: 99%

Emerging Cationic Nanovaccines

Carmona-Ribeiro,

Pérez-Betancourt

2024

Preprint

View full text Add to dashboard Cite

Nanovaccines are able to deliver antigen(s) and immunomodulator(s) directly to antigen-presenting cells (APCs) of the lymphatic system. Positive charges improve their uptake by APCs and often drive a Th-1 biased immune response so necessary against infectious diseases caused by intracellular pathogens and cancers. However, cationic compounds often display a dose-dependent toxicity so that systematic evaluation of cytotoxicity against cells in culture is required. After the rapid evolution of nanovaccines against SARS-Covid 2, mRNA vaccines gained much strength and have been designed against several infectious diseases, often relying on cationic components for mRNA protection. Once established the limiting concentration for the cationic compound, cationic nanovaccines perform well eliciting the desired Th-1 improved immune response in most cases. Other valuable approach found in the literature has been the construction of biocompatible nanoparticles (NPs) carrying cationic lipids, polymers or surfactants so that minimization of the concentration for the cationic component led to absence of toxicity. Against cancer, recent constructions of nanovaccines in situ after cancer cell disruption in the presence of adjuvants led to systemic presentation of multiple tumoral antigens yielding, in many instances, prevention of metastasis appearance and conversion of tumors non treatable by immunotherapy into treatable ones.

show abstract

Extracellular Vesicle‐Inspired Minimalist Flexible Nanocapsules Assembled with Whole Active Ingredients for Highly Efficient Enhancement of DC‐Mediated Tumor Immunotherapy

He,

Li,

Dang

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

The development of nanovaccines capable of eliciting tumor‐specific immune responses holds significant promise for tumor immunotherapy. However, many nanovaccine designs rely heavily on incorporating multiple adjuvants and carriers, increasing the biological hazards associated with these additional components. Here, this work introduces novel flexible nanocapsules (OVAnano) designed to mimic extracellular vesicles, primarily using the ovalbumin antigen and minimal polyethylenimine adjuvant components. These results show that the biomimetic flexible structure of OVAnano facilitates enhanced antigen uptake by dendritic cells (DCs), leading to efficient antigen and adjuvant release into the cytosol via endosomal escape, and ultimately, successful antigen cross‐presentation by DCs. Furthermore, OVAnano modulates the intracellular nuclear factor kappa‐B (NF‐κB) signaling pathway, promoting DC maturation. The highly purified antigens in OVAnano demonstrate remarkable antigen‐specific immunogenicity, triggering strong antitumor immune responses mediated by DCs. Therapeutic tumor vaccination studies have also shown that OVAnano administration effectively suppresses tumor growth in mice by inducing immune responses from CD8+ and CD4+ T cells targeting specific antigens, reducing immunosuppression by regulatory T cells, and boosting the populations of effector memory T cells. These findings underscore that the simple yet potent strategy of employing minimal flexible nanocapsules markedly enhances DC‐mediated antitumor immunotherapy, offering promising avenues for future clinical applications.

show abstract

Nanovaccines: An effective therapeutic approach for cancer therapy

Cited by 13 publications

References 323 publications

Nanomedicine: a frontier of the breast cancer treatment

Nanomedicine: a frontier of the breast cancer treatment

Emerging Cationic Nanovaccines

Extracellular Vesicle‐Inspired Minimalist Flexible Nanocapsules Assembled with Whole Active Ingredients for Highly Efficient Enhancement of DC‐Mediated Tumor Immunotherapy

Contact Info

Product

Resources

About